Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
Rhea-AI Summary
Lexicon Pharmaceuticals (Nasdaq: LXRX) will report third quarter 2025 financial results on Thursday, November 6, 2025, before market open. Management will host a conference call and live webcast on that day at 8:30 a.m. ET (7:30 a.m. CT) to discuss results and provide a business update.
Investors can access the live webcast via the company Events page at https://investors.lexpharma.com/. Participants who wish to ask questions must register to receive dial-in numbers and a unique PIN. An archived webcast will be posted on the Lexicon website after the call.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, LXRX gained 0.75%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
THE WOODLANDS, Texas, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its third quarter 2025 financial results on Thursday, November 6, 2025, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update.
Participants can access the conference call live via webcast on the Events page of the Company’s website at https://investors.lexpharma.com/. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. An archived version of the webcast will be available on the Lexicon website.
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000™ program, Lexicon’s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon has advanced multiple medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in heart failure, neuropathic pain, obesity, cardiology, diabetes and other indications. For additional information, please visit www.lexpharma.com.
For Investor and Media Inquiries:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com
FAQ
When will Lexicon Pharmaceuticals (LXRX) report Q3 2025 results?
What time is the Lexicon (LXRX) Q3 2025 earnings call and webcast?
How can investors access the Lexicon (LXRX) Q3 2025 webcast?
Can shareholders ask questions during the Lexicon (LXRX) Q3 2025 call?
Will Lexicon (LXRX) provide a replay of the Q3 2025 webcast?
